The “GT+TT” genotype of the IGFBP3 rs2854744, compared with the “GG” genotype, was associated with a 2.7-fold increased risk of NAFLD after adjustment for confounding factors (P = 0.009, OR = 2.71; 95%CI = 1.19-3.18). Here, IGFBP3 is linked to metabolic dysfunction-associated steatotic liver disease.